- Home
- XFLT vs EDIT Comparison
XFLT vs EDIT Comparison
Compare XFLT & EDIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | XFLT | EDIT |
|---|---|---|
| Founded | 2017 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 255.1M | 206.0M |
| IPO Year | N/A | 2016 |
Fundamental Metrics
Financial Performance| Metric | XFLT | EDIT |
|---|---|---|
| Price | $16.71 | $2.26 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $4.92 |
| AVG Volume (30 Days) | 624.3K | ★ 1.5M |
| Earning Date | 01-01-0001 | 03-09-2026 |
| Dividend Yield | ★ 14.17% | N/A |
| EPS Growth | N/A | ★ 37.50 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $31,937,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 132.64 |
| 52 Week Low | $3.02 | $0.91 |
| 52 Week High | $17.03 | $4.54 |
Technical Indicators
Market Signals| Indicator | XFLT | EDIT |
|---|---|---|
| Relative Strength Index (RSI) | 92.55 | 49.58 |
| Support Level | $4.93 | $2.01 |
| Resistance Level | N/A | $2.36 |
| Average True Range (ATR) | 0.27 | 0.15 |
| MACD | 1.50 | -0.03 |
| Stochastic Oscillator | 97.42 | 20.18 |
Price Performance
Historical ComparisonAbout XFLT XAI Octagon Floating Rate & Alternative Income Term Trust of Beneficial Interest
XAI Octagon Floating Rate & Alternative Income Trust is a diversified, closed-end management investment company which invests in a dynamically managed portfolio of floating-rate credit instruments and other structured credit investments within the private markets. The Trust's investment objective is to seek attractive total return with an emphasis on income generation across multiple stages of the credit cycle.
About EDIT Editas Medicine Inc.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.